Immuno Cure secures HK$8 M funding support for HIV vaccine clinical trial
Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, has announced that Hong Kong Science and Technology Parks Corporation (HKSTP) has awarded maximum amount of HK$8 million matching funding to Immuno Cure under the Clinical Translational Catalyst programme (CTC Programme) for conducting the Phase 1 Clinical Trial of ICVAX, a therapeutic vaccine against HIV/AIDS. The CTC Programme funding of HK$8 million will be drawn down by Immuno Cure in the next 27 months in various tranches according to the progress of the clinical trial of ICVAX. Immuno Cure previously received the University-Industry Collaboration Programme and Cash Rebate Scheme funding of some HK$8.4 million from the Government
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
